Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 221 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis				Phase IV				CZOL446EDE15 NCT00172003
	Sorafenib Hypophosphatemia Study				Phase IV				12345 N.A., NCT00622479
	Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®				Phase IV				A6181171 NCT00684645
	Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma				Phase IV				A6181132 NCT00706706
	Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors				Phase IV				UMCNONCO200801 NCT00777504
	Comparison Between Surgery and Radiofrequency for Treatment of Renal Tumors				Phase III, Phase II				9359-03 2003-006, NCT00221728
	ABR-217620 With Interferon-Alpha (IFN-Alpha) Compared to IFN-Alpha Alone in Patients With Advanced Renal Cell Carcinoma				Phase III, Phase II				06762004 NCT00420888
	SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma				Phase III				A6181034 NCT00083889
	Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma				Phase III				A6181037 NCT00130897
	Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery				Phase III				ECOG-E2805 E2805, CALGB-E2805, SWOG-E2805, CAN-NCIC-E2805, NCT00326898


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute